TARA - The Buzz Show: Protara Therapeutics Inc. (NASDAQ: TARA) FDA Clearance of Drug Application

FinancialBuzz.com’s latest The Buzz Show: Featuring Our Corporate News Recap on “Protara Therapeutics, Inc. Announces FDA Clearance of Investigational New Drug Application for TARA-002”

“The Buzz” Show: Protara Therapeutics, Inc. Announces FDA Clearance of Investigational New Drug Application for TARA-002

Protara Therapeutics, Inc. (NASDAQ: TARA) climbed over 15% in premarket trading after the U.S. FDA cleared the Company’s Investigational New Drug application for TARA-002

TARA-002 is an investigational cell-based therapy being developed for the treatment of non-muscle invasive bladder cancer, and Protara expects to initiate a Phase 1 clinical trial of TARA-002 in adults with high-grade NMIBC by the end of 2021.

For more information, please visit: Protara Therapeutics, Inc.

About The Buzz: A Financial Buzz Show on daily news, covering the most up to date financial information. The Buzz intends to provide factual and relevant information for its audience. The Buzz is 100% original content, created by Financial Buzz Media. Located on Wall Street in the heart of New York City’s financial district, FinancialBuzz.com is a credible source for the world’s latest trending financial and economic news. A pioneer in the financially driven digital space, video production and integration of social media, FinancialBuzz.com creates 100% unique original content.

The post “The Buzz” Show: Protara Therapeutics, Inc. (NASDAQ: TARA) FDA Clearance of Drug Application first appeared on Financial Buzz .

For further details see: